

Fonti bibliografiche LENTINEX

1. Xiao, Z, C.A. Trincado and M.P Murtaugh, 2004. β -Glucan enhancement of T cell IFNy response in swine. *Vet. Immunol. Immunopathol.*, 102:315-320. DOI: 10.1016/j.vetimm.2004.09.013.
2. Sonck, E., E. Stuyven, B. Goddeeris and E. Cox, 2010. The effect of β -glucans on porcine leukocytes. *Vet. Immunol. Immunopathol.*, 135: 199-207. DOI: 10.1016/j.vetimm.2009.11.014.
3. Samuelsen, A.B.C., J. Schrezenmeir and S.H. Knut- sen, 2014. Effects of orally administered yeast-derived beta-glucans: A review. *Mol. Nutr. Food Res.*, 58: 183-193. DOI: 10.1002/mnfr.201300338.
4. Vetzicka, V, 2011. Glucan-immunostimulant, adjuvant, potential drug. *World. J. Clin. Oncol.*, 2: 115- 119. DOI: 10.5306/WJCO.v2.i2.115.
5. Rubin-Bejerano, I., C. Abeijon, P. Magnelli, P. Grisati and G.R. Fink, 2007. Phagocytosis by human neutrophils is stimulated by a unique fungal cell wall component. *Cell Host Microbe*, 2: 55-67. DOI: 10.1016/j.chom.2007.06.002.
6. Zekovic, D.B., S. Kwiatkowski, M.M. Vrvic, D. Jakovljevic and C.A. Moran, 2005. Natural and modified (1 U3)- β -D-glucans in health promotion and disease alleviation. *Crit. Rev. Biotech* noi., 25: 205- 230. DOI: 10.1080/07388550500376166.
7. Czop, J.K., 1986. The role of β -glucan receptors on blood and tissue leukocytes in phagocytosis and metabolic activation. *Pathol. Immunopathol. Res.*, 5: 286-296. DOI: 10.1159/000157022.
8. Sandvik, A., Y.Y. Wang, H.C. Morton, A.O. Aasen and J.E. Wang et al., 2007. Oral and systemic administration of β -glucan protects against lipopolysaccharide-induced shock and organ injury in rats. *Clin. Exp. Immunol.*, 148: 168-177. DOI: 10.1111/j.1365-2249.2006.03320.x.
9. Akramiene, D., A. Kondrotas, J. Didziapetriene and E. Kevelaitis, 2007. Effects of beta-glucans on the immune system. *Medicina (Kaunas)*, 43: 597-606. PMID: 17895634.
10. Meira, D.A., PC. Pereira, J. Marcondes-Machado, R.P Mendes and B. Barraiera et al., 1996. The use of glucan as immunostimulant in the treatment of paracoccidioidomycosis. *Am. J. Trop. Med. Hyg.*, 55: 496-503. PMID: 8940980.
11. Pivarcsi, A., L. Bodai, B. Réthi, A. Kenderessy- Szabd and A. Koreck et al., 2003. Expression and function of Toll-like receptors 2 and 4 in human keratinocytes. *Int. Immunol.*, 15: 721-730. DOI: 10.1093/intimm/dxg068.
12. Thompson IM, Spence CR, Lamm DL, DiLuzio NR. Immunochemotherapy of bladder carcinoma with glucan and cyclophosphamide. *Am J Med Sci*. 1987;294:294-300.

13. Cancer Guide Compendio di abstracts.
14. Zhang L, Li X, Xu X, Zeng F. Correlation between antitumor activity, molecular weight, and conformation of lentinan. Carbohydr Res. 2005 Jun 13;340(8): 1515-21.
15. Joseph SI, Sabulal B, George V, Antony KR, Ja- nardhanan KK. Acta Pharm. 61 (2011) 335-342. Sep 1 ;61 (3):335-42. doi: 10.2478/v10007-011-0030-6.
16. Zhong Xi Yi Jie He Xue Bao. Antitumor and antiinflammatory activities of polysaccharides isolated from Ganoderma lucidum. 2006 Mar;4(2): 185-8.

The advertisement features a large, detailed 3D model of a COVID-19 virus particle (SARS-CoV-2) in the background, colored in shades of pink and purple. In the foreground, there is a small brown glass bottle of LENTINEX extract with a white cap. To the right of the bottle, two dried Ganoderma lucidum mushrooms are shown. The text on the left side of the bottle reads "Brevetto norvegese".

**L'IMMUNITÀ,
IL FARMACO
PIÙ POTENTE**

**Tecnica di fermentazione
unica e brevettata**
**Attivo già a 6 ore
dall'assunzione**
Inodore e insapore
**Efficace risposta
immunitaria**

Entra per maggiori informazioni

<https://www.erboristeriaracobaleno.it/prodotto/lentinex/>